Ondansetron Ratiopharm (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Ratiopharm, is a 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent nausea and vomiting caused by chemotherapy, postoperative recovery, and radiotherapy in adult patients.

GNH USA supplies Ondansetron Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical settings.

- Chemotherapy‑induced nausea and vomiting: prevents or reduces nausea and vomiting associated with cytotoxic chemotherapy. - Postoperative nausea and vomiting: helps control nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: reduces nausea and vomiting linked to radiation treatment.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heart rhythm beyond QT prolongation. - Hepatic dysfunction: abnormal liver enzyme elevations. - Neutropenia: reduced white blood cell count.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Cardiac assessment: review history of arrhythmias or prolonged QT interval. - Electrolyte monitoring: correct hypokalaemia, hypomagnesaemia, or hypocalcaemia before use. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant QT‑prolonging drugs: avoid or monitor closely when combined with other agents that affect cardiac repolarisation. - Renal function: adjust use in severe renal impairment if necessary. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Ondansetron may interact with other medications, altering efficacy or safety.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Anesthetic agents (e.g., propofol, volatile anesthetics): may enhance sedative effects. - Opioids (e.g., fentanyl, morphine): monitor for additive central nervous system depression.